Columnists
Tipsheet
Cartoons
Podcasts
Newsletters
Sections
Podcasts
Townhall TV
Election
Capitol Voices
Entertainment
Radio News
Live Blog
Topics
Sites
Hot Air
PJ Media
Bearing Arms
Twitchy
RedState
JOIN VIP
LOGIN
MY ACCOUNT
Account Settings
Newsletter Subscriptions
Log Out
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Apellis Pharmaceuticals Inc
(NQ:
APLS
)
29.47
-0.38 (-1.27%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 27, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Apellis Pharmaceuticals Inc
< Previous
1
2
3
4
5
6
7
8
9
...
16
17
Next >
Inside Cathie Wood’s Portfolio: 3 Stocks She Is Betting Millions On
November 01, 2023
Are you looking to invest in disrupting stocks like Cathie Woods? Here are three stocks Cathie Wood is betting millions on.
Via
InvestorPlace
10 Health Care Stocks Whale Activity In Today's Session
October 31, 2023
Via
Benzinga
Apellis Pharmaceuticals Stock Improves With An RS Ratings Over 90
October 31, 2023
Apellis Pharmaceuticals shows improving price performance, earning an upgrade to its IBD Relative Strength Rating.
Via
Investor's Business Daily
Apellis Pharmaceuticals to Host Conference Call on November 1, 2023, to Discuss Third Quarter 2023 Financial Results
October 25, 2023
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Analyst Ratings for Apellis Pharmaceuticals
October 06, 2023
Via
Benzinga
Why Apellis Pharmaceuticals Stock Popped Today
October 05, 2023
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) shares are trading higher Thursday after the company reported preliminary U.S.
Via
Benzinga
Why Shares of Apellis Pharmaceuticals Were Down Wednesday
September 27, 2023
A short-seller report sent the stock tumbling.
Via
The Motley Fool
Apellis Pharmaceuticals Stock Shows Rising Relative Strength
October 24, 2023
A Relative Strength Rating upgrade for Apellis Pharmaceuticals shows improving technical performance. Will it continue?
Via
Investor's Business Daily
The Lancet Publishes 24-Month Results from Phase 3 Studies of SYFOVRE® (pegcetacoplan injection) for Geographic Atrophy (GA)
October 20, 2023
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
10 Health Care Stocks Whale Activity In Today's Session
October 18, 2023
Via
Benzinga
Apellis to Present Positive Phase 2 NOBLE Results of Pegcetacoplan in Post-Transplant Recurrence of Primary IC-MPGN and C3G at Kidney Week
October 17, 2023
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Stocks Mixed Amid Earnings, Consumer Sentiment Data
October 13, 2023
Stocks are mixed this afternoon, as investors unpack earnings reports from several bank giants as well as economic data.
Via
Talk Markets
JPMorgan, Wells Fargo, Citigroup And Other Big Stocks Moving Higher On Friday
October 13, 2023
U.S. stocks traded mostly higher, with the Dow Jones gaining more than 100 points on Friday. Here are some big stocks recording gains in today’s session.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Why Pioneer Natural Resources Shares Are Bouncing By Around 12%; Here Are 20 Stocks Moving Premarket
October 06, 2023
Gainers Vaccinex, Inc. (NASDAQ: VCNX) shares rose 40.2% to $1.15 in pre-market trading as two large insider buys were reported after the close on Thursday.
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 6, 2023
October 06, 2023
Via
Benzinga
Constellation Brands To Rally Over 20%? Here Are 10 Other Analyst Forecasts For Friday
October 06, 2023
HSBC raised the price target for Constellation Brands, Inc. (NYSE: STZ) from $280 to $290. HSBC analyst Carlos Laboy maintained a Buy rating. Constellation shares fell 3.2% to close at $241.33 on...
Via
Benzinga
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 05, 2023
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Apellis Announces Preliminary U.S. Net Revenues of Approximately $74 Million for SYFOVRE® (pegcetacoplan injection) in the Third Quarter of 2023
October 05, 2023
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
APLS DEADLINE TODAY: ROSEN, A LEADING NATIONAL FIRM, Encourages Apellis Pharmaceuticals, Inc. Investors to Secure Counsel Before Important October 2 Deadline in Securities Class Action - APLS
October 02, 2023
WHY: NEW YORK, NY - (NewMediaWire) - October 2, 2023 - Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) between...
Via
TheNewswire.com
Topics
Lawsuit
Exposures
Financial
Legal
APLS DEADLINE TODAY: ROSEN, A LEADING NATIONAL FIRM, Encourages Apellis Pharmaceuticals, Inc. Investors to Secure Counsel Before Important October 2 Deadline in Securities Class Action - APLS
October 02, 2023
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Lawsuit
Exposures
Financial
Legal
NASDAQ:APLS Shareholder Alert: Deadline on October 2, 2023 Coming Up in Lawsuit Against Apellis Pharmaceuticals, Inc.
October 02, 2023
San Diego, CA -- (SBWIRE) -- 10/02/2023 -- A deadline is coming up on October 2, 2023 in the lawsuit filed for certain investors of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS).
Via
SBWire
Topics
Lawsuit
Exposures
Financial
Legal
Apellis Announces U.S. FDA Approval of the EMPAVELI® Injector, a Device to Streamline Self-Administration
October 02, 2023
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
APLS DEADLINE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Apellis Pharmaceuticals, Inc. Investors in Excess of $100K to Secure Counsel Before Important October 2 Deadline in Securities Class Action - APLS
September 30, 2023
WHY: NEW YORK, NY - (NewMediaWire) - September 29, 2023 - Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) between...
Via
TheNewswire.com
Topics
Lawsuit
Exposures
Financial
Legal
APELLIS 72 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against Apellis Pharmaceuticals, Inc. - APLS
September 29, 2023
From
Kahn Swick & Foti, LLC
Via
Business Wire
APELLIS DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Apellis Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm
September 29, 2023
From
Bragar Eagel & Squire, P.C.
Via
Business Wire
APLS DEADLINE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Apellis Pharmaceuticals, Inc. Investors in Excess of $100K to Secure Counsel Before Important October 2 Deadline in Securities Class Action - APLS
September 29, 2023
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Lawsuit
Exposures
Financial
Legal
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Apellis Pharmaceuticals, Inc. (APLS)
September 29, 2023
From
The Law Offices of Frank R. Cruz
Via
Business Wire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against RTX, Eos, and Apellis and Encourages Investors to Contact the Firm
September 27, 2023
From
Bragar Eagel & Squire
Via
GlobeNewswire
Why Sharps Technology Shares Are Trading Lower By Around 32%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
September 27, 2023
Gainers
Via
Benzinga
APELLIS PHARMACEUTICALS, INC. (NASDAQ: APLS) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Apellis Pharmaceuticals, Inc.
September 25, 2023
From
Bernstein Liebhard LLP
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
...
16
17
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.